For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250724:nRSX4508Sa&default-theme=true
RNS Number : 4508S Aptamer Group PLC 24 July 2025
24 July 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Result of General Meeting
Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce that, further to the Company's announcement on 4 July
2025, at its General Meeting held today, all Resolutions were passed.
Accordingly, all proposals outlined in the Company's circular dated 7 July
2025 (the "Circular") will proceed and 266,246,757 Conditional Placing Shares
(as defined in the announcement dated 4 July 2025) have been issued and
application has been made for the admission of these shares to trading on AIM,
which is expected to be effective from 8.00 am on or around 28 July 2025.
The full results of the voting will be published on the Company's website at
https://aptamergroup.com/investors/reports-and-presentations
(https://aptamergroup.com/investors/reports-and-presentations) .
Total Voting Rights
Immediately following Admission, the Company will have 2,660,978,377 Ordinary
Shares of £0.001 each in issue. The Company does not hold any shares in
treasury, and all of the Ordinary Shares have equal voting rights. Therefore,
the figures above represent the total voting rights in the Company and may be
used by shareholders as the denominator for the calculations by which they can
determine if they are required to notify their interest in, or a change to
their interest in the Company under the Rules.
- Ends -
For further information, please contact:
Aptamer Group plc +44 (0) 1904 217 404
Dr Arron Tolley
SPARK Advisory Partners Limited - Nominated Adviser +44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat
Turner Pope Investments (TPI) Limited - Broker +44 (0) 20 3657 0050
James Pope / Andrew Thacker
Northstar Communication Limited +44 (0) 113 730 3896
Sarah Hollins
About Aptamer Group plc
Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.
Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.
To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMPKQBQKBKDNOB